Pharmaids Pharmaceuticals share news, announcements and annual reports
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Pharmaids Pharmaceuticals Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994
Last close ₹28.42up ₹0.90 (3.27%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹27.52.
29 Oct: open ₹30.30, high ₹30.30, low ₹28.02
52-week range of traded prices to 29 Oct 2026
₹25.60Low, 1 Jun 2026₹53.90High, 9 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹100 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,010
Pharmaids Pharmaceuticals has 617 announcements on record, routine notices left out; none in the 30 days to 30 Oct 2026, the latest on 16 Sep 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Pharmaids Pharmaceuticals quarterly results
Aug12Wed
The board met on 12 Aug 2026 to consider quarterly results
Notice filed 6 Aug 2026
Pharmaids Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Pharmaids Pharmaceuticals financials, year by year
Annual reports29
- Annual report, year to Mar 202618 Aug 2026
- Annual report, year to Mar 202529 Aug 2025
- Annual report, year to Mar 20243 Sep 2024
- Annual report, year to Mar 202331 Aug 2023
- Annual report, year to Mar 202223 Jul 2022
24 earlier reports
- Annual report, year to Mar 202130 Aug 2021
- Annual report, year to Mar 202021 Aug 2020
- Annual report, year to Mar 20196 Sep 2019
- Annual report, year to Mar 20183 Oct 2018
- Annual report, year to Mar 201729 Sep 2017
- Annual report, year to Mar 20164 Oct 2016
- Annual report, year to Mar 20155 Sep 2015
- Annual report, year to Mar 201418 Jul 2014
- Annual report, year to Mar 20134 Sep 2013
- Annual report, year to Mar 2012Filing day not known
- Annual report, year to Mar 2011Filing day not known
- Annual report, year to Mar 2010Filing day not known
- Annual report, year to Mar 2009Filing day not known
- Annual report, year to Mar 2008Filing day not known
- Annual report, year to Mar 2007Filing day not known
- Annual report, year to Mar 2006Filing day not known
- Annual report, year to Mar 2005Filing day not known
- Annual report, year to Mar 2004Filing day not known
- Annual report, year to Mar 2003Filing day not known
- Annual report, year to Mar 2002Filing day not known
- Annual report, year to Mar 2000Filing day not known
- Annual report, year to Mar 1999Filing day not known
- Annual report, year to Mar 1998Filing day not known
- Annual report, year to Mar 1997Filing day not known
Pharmaids Pharmaceuticals merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings7
- Dear Sir, Please find attached as per SEBI Circular No. CFD/DIL3/CIR/2017/21 dated March 10th,2017 Submission of documents post approval of the Scheme by National Company Law Tribunal (NCLT) ....18 Nov 2019
- Dear Sir, Please find attached Intimation Record date for allotment of Equity Shares pursuant to Scheme of Amalgamation ('Scheme') of Emergent Bio Naturals Limited ("Transferor ....13 Nov 2019
- This is in continuation to our earlier communication regarding receipt of approval of National Company Law Tribunal, Hyderabad (NCLT) vide their order dated September 27, 2019 for the Scheme ....1 Nov 2019
- Dear Sir, Approval of the National Company Law Tribunal to the Scheme of Amalgamation of Emergent Bio Naturals Ltd with Pharmaids Pharmaceuticals Ltd and their respective shareholders ....30 Sep 2019
- Dear Sir, Please find the attachment of Abridge Prospectus of unlisted entity and certification by Merchant Banker. Kindly take the same on your record Thanks®ards ....27 Aug 2019
2 earlier filings
- Dear sir, With reference to the above subject we inadvertently filed the news paper advertisement under CIRP instead of Regulation 30 (LODR), now we filed correctly under Regualtion ....11 Jul 2019
- Dear Sir, This is in reference to the scheme of Amalgamation of Emergent Bio Naturals Limited and Pharmaids Pharmaceuticals Limited and their respective shareholders under section ....11 Jul 2019
Pharmaids Pharmaceuticals share news and announcements
Newest first. Page 1 of 13.
Sep 2026
16 Sep · Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Aug 2026
18 Aug · Meeting
12 Aug · Results
12 Aug · Results
6 Aug · Board meeting
Meeting on 12 Aug 2026: quarterly results
Jun 2026
13 Jun · Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Providing Corporate Guarantee To Subsidiary
May 2026
22 May · Board meeting
Meeting on 29 May 2026: audited results
Mar 2026
27 Mar · Intimation Under Regulation 30 Of SEBI LODR
Feb 2026
24 Feb · Intimation Of Receipt Of Accreditation By The American Association For Laboratory Accreditation (A2LA) For Testing Of Medical Devices In Biological Field.
9 Feb · Board meeting
Meeting on 12 Feb 2026: quarterly results
Jan 2026
5 Jan · Outcome Of The Circular Resolution Dated 05Th January 2026.
Dec 2025
10 Dec · Management
Nov 2025
29 Nov · Meeting
28 Nov · Outcome Of The Circular Resolution Dated 28Th November 2025.
6 Nov · Board meeting
Meeting on 11 Nov 2025: quarterly results
Sep 2025
18 Sep · Business
6 Sep · Announcement Under Regulation 30 - Intimation Of Registration Of Sale Deed.
Aug 2025
29 Aug · Announcement under Regulation 30 (LODR)-Open Offer - Updates
29 Aug · Post Offer Advertisement
21 Aug · Management
21 Aug · Board meeting
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 1 Jul 2026Board or managers changeddown 5.93%−6.4 pts vs Nifty 500market median 0.0% · five sessions −11.0% (−12.6 pts vs Nifty 500) · volume 2.1× usual · The announcement
- 29 Jun 2026Board or managers changedup 0.82%+1.3 pts vs Nifty 500market median 0.0% · five sessions −7.7% (−8.5 pts vs Nifty 500) · volume 1.5× usual · The announcement
- 6 Jan 2026Board or managers changeddown 4.10%−3.9 pts vs Nifty 500market median 0.0% · five sessions −2.6% (−0.3 pts vs Nifty 500) · volume 0.8× usual · The announcement
- 2 Jan 2026Board or managers changeddown 3.42%−4.2 pts vs Nifty 500market median 0.0% · five sessions +0.2% (+1.1 pts vs Nifty 500) · volume 1.1× usual · The announcement
- 11 Dec 2025Board or managers changedup 0.28%−0.3 pts vs Nifty 500market median 0.0% · five sessions −3.7% (−4.1 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 1 Dec 2025Board or managers changeddown 4.13%−4.1 pts vs Nifty 500market median 0.0% · five sessions +9.8% (+10.2 pts vs Nifty 500) · volume 1.7× usual · The announcement
- 25 Sep 2025Board or managers changedup 2.02%+2.7 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−1.0 pts vs Nifty 500) · volume 1.4× usual · The announcement
- 8 Aug 2025Board or managers changeddown 0.30%+0.8 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−2.0 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 7 Jul 2025Board or managers changeddown 1.44%−1.4 pts vs Nifty 500market median 0.0% · five sessions +10.4% (+11.5 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 27 Mar 2025Board or managers changeddown 0.96%−1.6 pts vs Nifty 500market median 0.0% · five sessions +3.2% (+3.4 pts vs Nifty 500) · volume 1.0× usual · The announcement
16 earlier announcements
- 13 Feb 2025Board or managers changedup 0.45%+0.5 pts vs Nifty 500market median 0.0% · five sessions −8.4% (−7.6 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 6 Aug 2024Board or managers changeddown 1.20%−0.8 pts vs Nifty 500market median 0.0% · five sessions −3.1% (−4.8 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 29 May 2024Board or managers changeddown 2.14%−1.5 pts vs Nifty 500market median 0.0% · five sessions −7.5% (−2.6 pts vs Nifty 500) · volume 1.4× usual · The announcement
- 27 May 2024Board or managers changedup 0.05%0.0 pts vs Nifty 500market median 0.0% · five sessions −9.9% (−8.1 pts vs Nifty 500) · volume 1.2× usual · The announcement
- 24 May 2024Board or managers changeddown 1.99%−2.0 pts vs Nifty 500market median 0.0% · five sessions −11.1% (−9.0 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 12 Feb 2024Board or managers changeddown 4.99%−3.6 pts vs Nifty 500market median 0.0% · five sessions −5.3% (−6.3 pts vs Nifty 500) · volume 0.7× usual · The announcement
- 8 Jan 2024Board or managers changedup 4.99%+5.9 pts vs Nifty 500market median 0.0% · five sessions +15.4% (+14.7 pts vs Nifty 500) · volume 2.8× usual · The announcement
- 30 Aug 2023Board or managers changeddown 4.85%−5.1 pts vs Nifty 500market median 0.0% · five sessions −3.2% (−5.1 pts vs Nifty 500) · volume 1.9× usual · The announcement
- 4 Aug 2023Board or managers changeddown 1.99%−2.7 pts vs Nifty 500market median 0.0% · five sessions −9.5% (−10.5 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 23 Jan 2023Board or managers changedup 4.98%+4.3 pts vs Nifty 500market median 0.0% · five sessions +13.6% (+15.8 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 14 Oct 2022Board or managers changedup 1.41%+0.8 pts vs Nifty 500market median 0.0% · five sessions +0.7% (−1.9 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 4 Aug 2022Board or managers changedup 1.89%+1.8 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−3.4 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 11 Jul 2022Board or managers changedup 2.71%+2.3 pts vs Nifty 500market median 0.0% · five sessions +1.3% (+1.6 pts vs Nifty 500) · volume 0.9× usual · The announcement
- 23 Nov 2020Board or managers changedup 1.99%+1.3 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+8.8 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 31 Jul 2020Board or managers changed–market median 0.0% · five sessions −22.1% (−28.1 pts vs Nifty 500) · volume 0.5× usual · The announcement
- 10 Dec 2012Board or managers changeddown 4.97%−5.1 pts vs Nifty 500market median 0.0% · five sessions −21.0% (−20.4 pts vs Nifty 500) · volume 0.0× usual
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Other cash from financing | Year to date to Mar 2026 | Consolidated | −0.81 | −0.81 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Cash at the end of the period | At Mar 2026 | Consolidated | 0.13 | 0.13 | +0.1% | 30 May 2026 | 1 Jun 2026 |
| Net change in cash | Year to Mar 2026 | Consolidated | −0.69 | −0.69 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Net change in cash | Year to date to Mar 2026 | Consolidated | −0.69 | −0.69 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Net change in cash, before currency effects | Year to Mar 2026 | Consolidated | −0.69 | −0.69 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Net change in cash, before currency effects | Year to date to Mar 2026 | Consolidated | −0.69 | −0.69 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Cash from financing | Year to Mar 2026 | Consolidated | −19.97 | −19.97 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Cash from financing | Year to date to Mar 2026 | Consolidated | −19.97 | −19.97 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Other cash from financing | Year to Mar 2026 | Consolidated | −0.81 | −0.81 | 0.0% | 30 May 2026 | 1 Jun 2026 |
| Borrowings repaid | Year to date to Mar 2026 | Standalone | −25.79 | 25.79 | +200.0% | 29 May 2026 | 1 Jun 2026 |